Q4 EPS Estimates for Cooper Companies Lowered by KeyCorp

Key Points

• KeyCorp cut Cooper Companies’ Q4 2026 EPS forecast to $1.06 from $1.21, while maintaining a “Sector Weight” rating. The company’s Q4 guidance is $1.05–$1.09 per share, compared with full-year guidance of $4.51–$4.55.
• Cooper reported quarterly EPS of $1.15, beating expectations of $1.12, but revenue of $1.07 billion fell short of the $1.10 billion consensus estimate. Analysts remain cautious, with an overall “Hold” rating and a consensus price target of $71.47.
• The board authorized a $3 billion share-repurchase program, covering up to 22.7% of outstanding shares, while company directors bought shares during the recent selloff. However, ongoing inventory destocking, activist investor pressure and legal investigations add near-term uncertainty.

The Cooper Companies, Inc. (NASDAQ:COO - Free Report) - KeyCorp decreased their Q4 2026 EPS estimates for shares of Cooper Companies in a report issued on Wednesday, September 9th. KeyCorp analyst B. Fishbin now anticipates that the medical device company will earn $1.06 per share for the quarter, down from their previous forecast of $1.21. KeyCorp currently has a "Sector Weight" rating on the stock. The consensus estimate for Cooper Companies' current full-year earnings is $4.53 per share.

COO has been the topic of several other reports. Weiss Ratings raised Cooper Companies from a "sell (d)" rating to a "hold (c-)" rating in a report on Friday. BNP Paribas Exane lowered their price objective on Cooper Companies from $95.00 to $92.00 and set an "outperform" rating on the stock in a research report on Monday, June 8th. Stifel Nicolaus set a $70.00 price objective on shares of Cooper Companies and gave the stock a "buy" rating in a research note on Thursday, September 10th. William Blair lowered shares of Cooper Companies from an "outperform" rating to a "market perform" rating in a report on Thursday, September 10th. Finally, Piper Sandler lowered shares of Cooper Companies from an "overweight" rating to a "neutral" rating and cut their target price for the company from $86.00 to $59.00 in a report on Thursday, September 10th. Five equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $71.47.

Cooper Companies Stock Performance

NASDAQ COO opened at $55.29 on Monday. The firm has a market capitalization of $10.51 billion, a P/E ratio of 18.87, a PEG ratio of 2.25 and a beta of 0.82. The stock has a 50-day simple moving average of $69.92 and a two-hundred day simple moving average of $68.57. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.73 and a current ratio of 1.22. Cooper Companies has a fifty-two week low of $51.01 and a fifty-two week high of $89.83.

Cooper Companies (NASDAQ:COO - Get Free Report) last issued its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.03. The firm had revenue of $1.07 billion during the quarter, compared to analysts' expectations of $1.10 billion. Cooper Companies had a net margin of 13.46% and a return on equity of 10.90%. The firm's revenue was up .5% compared to the same quarter last year. During the same quarter last year, the company posted $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS.

Cooper Companies declared that its board has authorized a stock repurchase program on Wednesday, September 9th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the medical device company to reacquire up to 22.7% of its stock through open market purchases. Stock buyback programs are often an indication that the company's leadership believes its shares are undervalued.

Insider Activity at Cooper Companies

In other Cooper Companies news, Director Walter Rosebrough, Jr. purchased 7,000 shares of Cooper Companies stock in a transaction that occurred on Friday, September 11th. The stock was bought at an average price of $54.11 per share, with a total value of $378,770.00. Following the acquisition, the director owned 17,000 shares of the company's stock, valued at $919,870. This trade represents a 70.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Lawrence Kurzius purchased 10,000 shares of the stock in a transaction on Monday, September 14th. The shares were acquired at an average price of $53.91 per share, for a total transaction of $539,100.00. Following the transaction, the director directly owned 21,099 shares of the company's stock, valued at $1,137,447.09. This represents a 90.10% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 34,701 shares of company stock worth $1,880,039 in the last 90 days. Corporate insiders own 2.08% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in COO. Root Financial Partners LLC raised its position in Cooper Companies by 104.5% during the fourth quarter. Root Financial Partners LLC now owns 317 shares of the medical device company's stock worth $26,000 after acquiring an additional 162 shares during the period. Avalon Trust Co purchased a new position in Cooper Companies during the second quarter valued at $25,000. SJS Investment Consulting Inc. grew its position in shares of Cooper Companies by 107.5% in the first quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company's stock valued at $26,000 after purchasing an additional 187 shares during the period. Elevation Wealth Partners LLC grew its position in shares of Cooper Companies by 1,136.4% in the second quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company's stock valued at $29,000 after purchasing an additional 375 shares during the period. Finally, Continuum Advisory LLC purchased a new stake in shares of Cooper Companies during the second quarter worth about $30,000. Hedge funds and other institutional investors own 24.39% of the company's stock.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Activist investor Jana Partners urged Cooper to conduct an external CEO search, appoint a new board chair and evaluate asset sales. Although the campaign highlights execution problems, investors may view potential leadership and portfolio changes as catalysts for unlocking shareholder value. Reuters activist investor report
• Positive Sentiment: Several directors have recently bought shares, including Lawrence Kurzius’s purchase of 10,000 shares for approximately $549,300. The cluster of insider buying may signal that directors view the selloff as excessive. Director insider purchase report
• Positive Sentiment: Cooper retained CooperSurgical after its strategic review and expanded its share-repurchase authorization to $3 billion. The buyback, combined with reported record free cash flow and an adjusted EPS beat, supports the long-term shareholder-value case. Cooper Companies strategic review and capital plan article
• Neutral Sentiment: Jana’s campaign could lead to strategic improvements, but it also increases uncertainty around management, the board and Cooper’s business portfolio.
• Negative Sentiment: U.S. channel inventory destocking at CooperVision is expected to continue into the fourth quarter, raising questions about near-term demand and revenue growth. The company’s latest quarter beat EPS expectations but missed revenue estimates.
• Negative Sentiment: Investor-law-firm investigations related to the guidance reduction add legal and headline risk, while cautious analyst ratings and prior target-price cuts reflect Cooper’s underperformance versus medical-device peers. Securities investigation notice

Cooper Companies Company Profile

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.